Browse by author
Lookup NU author(s): Professor Vishna Devi V NadarajahORCiD, Dr Amina Chaouch, Dr Penelope Garrood, Professor Volker StraubORCiD, Professor Hanns Lochmuller
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
To identify serum biomarkers that allow monitoring of disease progression and treatment effects in Duchenne muscular dystrophy (DMD) patients, levels of matrix metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase-1 (TIMP-1) and osteopontin (OPN) were determined in 63 DMD patients on corticosteroid therapy. These proteins were selected for their role in the pathogenesis of muscular dystrophy. Levels of MMP-9 and TIMP-1 were significantly higher in sera of DMD patients compared to healthy controls, whereas the OPN levels showed no significant difference. MMP-9 levels were also observed to be significantly higher in older, nonambulant patients, compared to ambulant patients. Longitudinal data from a smaller cohort of DMD patients followed up for over 4 years showed that MMP-9, but not TIMP-1 increased significantly with age. Hence, MMP-9 is a potential DMD biomarker for disease progression. Future studies have to confirm whether serum MMP-9 levels can be used to monitor therapeutic response. (C) 2011 Elsevier B.V. All rights reserved.
Author(s): Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, Lochmuller H, Ginjaar HB, Aartsma-Rus AM, van Ommen GJB, den Dunnen JT, 't Hoen PAC
Publication type: Article
Publication status: Published
Journal: Neuromuscular Disorders
Year: 2011
Volume: 21
Issue: 8
Pages: 569-578
Print publication date: 02/07/2011
ISSN (print): 0960-8966
ISSN (electronic): 1873-2364
Publisher: Elsevier Ltd
URL: http://dx.doi.org/10.1016/j.nmd.2011.05.011
DOI: 10.1016/j.nmd.2011.05.011
PubMed id: 21724396
Altmetrics provided by Altmetric
